SuperworthCytek Biosciences profit margin CTKB
Gross, operating and net profit as a share of revenue over the last twelve months, from 2020.
- Net margin, 12 months
- −39.0%
- Operating margin, 12 months
- −21.6%
- Net margin on a year earlier
- −35.7 pts
- Peer median
- 13.6%
Over the twelve months to Jun 30, 2026, Cytek Biosciences kept −39.0% of its revenue as net profit, with an operating margin of −21.6% and a gross margin of 53.2%.
Five years earlier its net margin was 13.5%.
The median for 6 diagnostics and research stocks of a similar size is 13.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −33.0% | −20.0% | 51.8% |
| FY2024 | −3.0% | −10.2% | 55.4% |
| FY2023 | −6.3% | −14.4% | 56.7% |
| FY2022 | 1.4% | −1.1% | 61.6% |
| FY2021 | 2.4% | 7.2% | 61.9% |
| FY2020 | 20.9% | 14.7% | 55.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −39.0% | −35.7 pts | −21.6% | |
| Q1 FY26 | −36.2% | −30.5 pts | −21.5% | |
| Q4 FY25 | −33.0% | −30.0 pts | −20.0% | |
| Q3 FY25 | −6.5% | −1.5 pts | −16.2% | |
| Q2 FY25 | −3.3% | +5.6 pts | −13.7% | |
| Q1 FY25 | −5.7% | +0.0 pts | −12.6% | |
| Q4 FY24 | −3.0% | +3.3 pts | −10.2% | |
| Q3 FY24 | −5.0% | +2.7 pts | −11.8% | |
| Q2 FY24 | −8.9% | −5.5 pts | −13.1% | |
| Q1 FY24 | −5.7% | −4.3 pts | −13.2% | |
| Q4 FY23 | −6.3% | −7.7 pts | −14.4% | |
| Q3 FY23 | −7.7% | −6.2 pts | −15.1% |
Against its peers
Companies in Medical - Diagnostics & Research nearest Cytek Biosciences' size, closest first, today.
| Company | Profit margin |
|---|---|
| CTKBCytek Biosciences | −39.0% |
| NRCNRC Health | 4.2% |
| CDNACareDx | 24.2% |
| VCYTVeracyte | 20.4% |
| BLLNBillionToOne | 9.5% |
| ICCCImmucell | 2.6% |
| LNTHLantheus | 17.7% |
| Peer median | 13.6% |
Where Cytek Biosciences ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Cytek Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.